Eliot L. Gardner, Ph.D., Chief - Principal Investigators - The Intramural Research Program of the National Institute on Drug Abuse

Skip Navigation


photo of Dr. Gardner


251 Bayview Blvd
Suite 200, Room 05A707
Baltimore, MD 21224

Phone: 443-740-2516
Fax: 443-740-2781


Eliot L. Gardner, Ph.D., Senior Investigator

Chief, Neuropsychopharmacology Section

Postdoctoral training – Neurology. Albert Einstein College of Medicine

Postdoctoral training – Pharmacology. Albert Einstein College of Medicine

Ph.D. (First class honours) – Physiological Psychology. McGill University

M.A. (Honours) – Experimental Psychology and Psychopharmacology. McGill University

A.B. (cum laude) – Psychology. Harvard University


  • Basic brain mechanisms underlying drug addiction, craving, and relapse
  • Endocannabinoid brain mechanisms and addiction
  • Dopamine D3 receptor antagonists
  • Glutamatergic compounds, with emphasis on the metabotropic glutamate receptor
  • GABAergic agonists, with emphasis on the GABA-B receptor
  • Slow-onset long-acting dopamine transport inhibitors
  • Drugs acting on the endocannabinoid brain system
Research in all these areas is directed toward the development of effective anti-addiction, anti-craving, anti-relapse medications.

Selected Publications:

View more publications at PubMed.

More about Dr. Gardner

Health and Human Services Logo National Institute on Drug Abuse Logo

The National Institute on Drug Abuse (NIDA), is part of the National Institutes of Health (NIH), the principal biomedical and behavioral research agency of the United States Government. NIH is a component of the U.S. Department of Health and Human Services.

PDF documents require the free Adobe Reader. Microsoft Word documents require the free Microsoft Word viewer. Microsoft PowerPoint documents require the free Microsoft PowerPoint viewer. Flash content requires the free Adobe Flash Player.